TP53 and metastatic neoplasm: Yilmaz et al. conducted whole-exome and targeted sequencing of metastatic and localized cSCC and found increased TP53 mutation frequencies in metastatic disease compared to localized disease (85% vs. 54%, respectively; p < 0.0001).